Changes

==Common Alteration Types==

==Common Alteration Types==

By far the most common ABL1 alteration associated with cancer is the BCR-ABL1 fusion as described above in CML and ALL.  

By far the most common ''ABL1'' alteration associated with cancer is the BCR-ABL1 fusion as described above in CML and ALL.  

A number of other gene fusion partners have been identified with ''ABL1'' that are linked to hematological cancers, but at a much smaller prevalence than BCR-ABL1.

A number of other gene fusion partners have been identified with ''ABL1'' that are linked to hematological cancers, but at a much smaller prevalence than BCR-ABL1.

Somatic mutations for ''ABL1'' have been found in Lung Squamous Cell Carcinomas patients (2%), Uterine Corpus Endometrioid Carcinoma patients (3%) and in less than 1% of patients with Breast Invasive Carcinoma, Ovarian Serous Cystadenocarcinoma, and Lung Adenocarcinoma [6].

Somatic mutations for ''ABL1'' have been found in Lung Squamous Cell Carcinomas patients (2%), Uterine Corpus Endometrioid Carcinoma patients (3%) and in less than 1% of patients with Breast Invasive Carcinoma, Ovarian Serous Cystadenocarcinoma, and Lung Adenocarcinoma [6].

Resistance to tyrosine kinase inhibitors (eg, Gleevec) are attributed to secondary mutations within the tyrosine kinase domain of ''ABL1'', especially the "gatekeeper" T315I residue mutation [7,8].

Resistance to tyrosine kinase inhibitors (e.g., Gleevec) are attributed to secondary mutations within the tyrosine kinase domain of ''ABL1'', especially the "gatekeeper" T315I residue mutation [7,8].

{| class="wikitable sortable"

{| class="wikitable sortable"